TL;DR
The oral GLP-1 market is rapidly maturing as Novo Nordisk leverages its commercial lead over Eli Lilly's newly launched Foundayo to clinically validate patient "microdosing" patterns. Meanwhile, independent challenger Viking Therapeutics is preparing to enter Phase 3 trials with its own oral candidate while diversifying into alternative, amylin-based weight loss mechanisms.
The Oral GLP-1 Race and the "Microdosing" Response
The oral weight-loss market is shifting from a pure volume grab to a clinical race for dosage flexibility as manufacturers adapt to real-world patient behaviors.
"People are using low dosages of these products... they just decide on their own." — Mike Doustdar, Novo Nordisk CEO via eli-lilly-foundayo-orforglipron-fda-approval
"OASIS 5 is designed to evaluate the efficacy and safety of lower maintenance doses of the Wegovy pill in adults with overweight or obesity. While the currently approved maintenance dose is 25 mg, we are also studying the effects of lower maintenance doses by generating new evidence to fully reflect the patients’ needs in real-world obesity management." — Novo Nordisk Corporate Statement via eli-lilly-foundayo-orforglipron-fda-approval
Novo Nordisk is using its commanding early lead—with its oral Wegovy pill posting Q2 sales of roughly $498 million compared to just $98 million for Eli Lilly's newly launched competitor, Foundayo—to pivot toward long-term patient retention eli-lilly-foundayo-orforglipron-fda-approval. By initiating the OASIS-5 trial to evaluate lower maintenance doses, Novo is directly addressing the self-directed "microdosing" trend driven by patient side effects and high costs eli-lilly-foundayo-orforglipron-fda-approval
.
What to watch: Watch whether Eli Lilly introduces its own low-dose clinical trials for Foundayo to counter Novo's real-world flexibility strategy eli-lilly-foundayo-orforglipron-fda-approval.
Biotech Challengers Expand Beyond Incretins
Mid-sized biotech challengers are aggressively moving to disrupt the established duopoly by advancing oral formulations and pioneering alternative weight-loss mechanisms.
"With respect to our lead compound, VK2735, Viking's Phase 3 VANQUISH-1 and -2 trials are fully enrolled and proceeding according to plan... Also during the second quarter, Viking expanded its obesity portfolio with the initiation of a Phase 1 clinical trial of VK3019, an investigational amylin receptor agonist." — Brian Lian, Ph.D., Viking CEO via viking-therapeutics-oral-vk2735-phase-2-venture
Viking Therapeutics is positioning itself as a formidable competitor by preparing a Q4 2026 Phase 3 launch for oral VK2735, backed by Phase 2 data showing 12% weight loss over 13 weeks viking-therapeutics-oral-vk2735-phase-2-venture. Furthermore, by initiating clinical trials for its amylin agonist VK3019, Viking is diversifying into non-incretin pathways to capture patients who cannot tolerate traditional GLP-1 therapies viking-therapeutics-oral-vk2735-phase-2-venture
.
What to watch: Watch for Viking's upcoming Phase 1 maintenance study results in late Q3 2026, which could validate less frequent dosing schedules like biweekly or monthly regimens viking-therapeutics-oral-vk2735-phase-2-venture.
What surprised us
- Novo's Pivot to "Microdosing" Science: It is surprising to see a major pharmaceutical developer officially embrace patient-led "microdosing" by launching the OASIS-5 trial specifically to study lower-than-approved maintenance doses of the Wegovy pill eli-lilly-foundayo-orforglipron-fda-approval
.
- Foundayo's Quiet Debut: Despite Eli Lilly's massive market footprint, its daily oral GLP-1 Foundayo brought in only $98 million in its first partial quarter, showing how difficult it is to immediately shake Novo's early oral dominance eli-lilly-foundayo-orforglipron-fda-approval
- Viking's Massive R&D Ramp: Viking Therapeutics nearly doubled its quarterly R&D expenses to $115.8 million, demonstrating the immense capital required for a biotech challenger to run concurrent Phase 3 obesity trials viking-therapeutics-oral-vk2735-phase-2-venture
.